MIRCETTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MIRCETTE (MIRCETTE).
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass hepatic metabolism, conjugated to sulfate and glucuronide. Desogestrel: prodrug converted to active metabolite etonogestrel via CYP2C9 and CYP3A4; further metabolized by reduction and glucuronidation. |
| Excretion | Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites) |
| Half-life | Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours |
| Protein binding | Desogestrel: >95% (albumin, SHBG); ethinyl estradiol: >97% (albumin) |
| Volume of Distribution | Desogestrel: 1.5 L/kg; ethinyl estradiol: 2.9 L/kg |
| Bioavailability | Desogestrel (as etonogestrel): 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism) |
| Onset of Action | Oral administration: 7 days of continuous use for contraceptive effect (inhibition of ovulation) |
| Duration of Action | Contraceptive effect persists for 7 days after last pill if taken correctly; withdrawal bleed occurs during placebo week |
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended. Use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C) or liver tumors. For mild to moderate impairment (Child-Pugh A-B), use with caution; contraindicated if liver function tests are persistently abnormal. |
| Pediatric use | Not indicated in prepubertal females. Safety and efficacy in postmenarchal adolescents established based on adult studies. |
| Geriatric use | Contraindicated in postmenopausal women. Not indicated for use in elderly due to lack of efficacy for contraception. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MIRCETTE (MIRCETTE).
| Breastfeeding | Excreted into breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infant (adrenal suppression, hormonal imbalance). Contraindicated during breastfeeding per manufacturer. |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/third trimester exposure may cause fetal adrenal suppression, virilization of female fetus, and metabolic disturbances. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from COC use, especially in women >35 years old who smoke ≥15 cigarettes/day. Do not prescribe to women who smoke and are over 35.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease (current or history)","Known or suspected breast carcinoma","Carcinoma of endometrium or other known/suspected estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma (current or history)","Known or suspected pregnancy","Hypersensitivity to any component","Smoking and age >35 years","Migraine with aura (current or history) in women over 35"]
| Precautions | ["Increased risk of thrombotic disorders (VTE, MI, stroke), especially in smokers and women with hypertension or other risk factors.","Liver disease: discontinue if jaundice or impaired liver function develops.","Elevated blood pressure: monitor and discontinue if hypertension develops.","Gallbladder disease: possible increased risk.","Carbohydrate and lipid metabolism: monitor in diabetic or hyperlipidemic patients.","Headache: may exacerbate migraine or cause new-onset headache.","Uterine bleeding: irregular bleeding may occur.","Depression: discontinue if significant depression occurs.","Ocular effects: discontinue if sudden partial/complete vision loss occurs.","Carcinoma: possible increased risk of breast/cervical cancer, but evidence uncertain."] |
Loading safety data…
| Fetal Monitoring |
| Pregnancy testing before initiation and periodically during therapy. Ultrasound for fetal development if accidental exposure occurs. Monitor maternal blood pressure, glucose, and liver function. Assess fetal heart rate if late exposure. |
| Fertility Effects | Reversible suppression of ovulation. Return to fertility typically within 2-3 cycles after discontinuation. Long-term use may delay return to fertility but no permanent effect. |